Literature DB >> 27326316

Redefining Budd-Chiari syndrome: A systematic review.

Naomi Shin1, Young H Kim1, Hao Xu1, Hai-Bin Shi1, Qing-Qiao Zhang1, Jean Paul Colon Pons1, Ducksoo Kim1, Yi Xu1, Fei-Yun Wu1, Samuel Han1, Byung-Boong Lee1, Lin-Sun Li1.   

Abstract

AIM: To re-examine whether hepatic vein thrombosis (HVT) (classical Budd-Chiari syndrome) and hepatic vena cava-Budd Chiari syndrome (HVC-BCS) are the same disorder.
METHODS: A systematic review of observational studies conducted in adult subjects with primary BCS, hepatic vein outflow tract obstruction, membranous obstruction of the inferior vena cava (IVC), obliterative hepatocavopathy, or HVT during the period of January 2000 until February 2015 was conducted using the following databases: Cochrane Library, CINAHL, MEDLINE, PubMed and Scopus.
RESULTS: Of 1299 articles identified, 26 were included in this study. Classical BCS is more common in women with a pure hepatic vein obstruction (49%-74%). HVC-BCS is more common in men with the obstruction often located in both the inferior vena cava and hepatic veins (14%-84%). Classical BCS presents with acute abdominal pain, ascites, and hepatomegaly. HVC-BCS presents with chronic abdominal pain and abdominal wall varices. Myeloproliferative neoplasms (MPN) are the most common etiology of classical BCS (16%-62%) with the JAK2V617-F mutation found in 26%-52%. In HVC-BCS, MPN are found in 4%-5%, and the JAK2V617-F mutation in 2%-5%. Classical BCS responds well to medical management alone and 1(st) line management of HVC-BCS involves percutaneous recanalization, with few managed with medical management alone.
CONCLUSION: Systematic review of recent data suggests that classical BCS and HVC-BCS may be two clinically different disorders that involve the disruption of hepatic venous outflow.

Entities:  

Keywords:  Budd-Chiari; Hepatic vein outflow tract obstruction; Hepatic vein thrombosis; Membranous obstruction of the inferior vena cava; Obliterative hepatocavopathy

Year:  2016        PMID: 27326316      PMCID: PMC4909431          DOI: 10.4254/wjh.v8.i16.691

Source DB:  PubMed          Journal:  World J Hepatol


  48 in total

1.  Surgical treatment of 1360 cases of Budd-Chiari syndrome: 20-year experience.

Authors:  Pei-Qin Xu; Xiu-Xian Ma; Xue-Xiang Ye; Liu-Shun Feng; Xiao-Wei Dang; Yong-Fu Zhao; Shui-Jun Zhang; Long-Shuan Zhao; Zhe Tang; Xiu-Bo Lu
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2004-08

2.  Vascular disorders of the liver.

Authors:  Laurie D DeLeve; Dominique-Charles Valla; Guadalupe Garcia-Tsao
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

3.  Occurrence of the JAK2 V617F mutation in the Budd-Chiari syndrome.

Authors:  Donatella Colaizzo; Lucio Amitrano; Giovanni L Tiscia; Luigi Iannaccone; Anna Gallone; Elvira Grandone; Maria A Guardascione; Maurizio Margaglione
Journal:  Blood Coagul Fibrinolysis       Date:  2008-07       Impact factor: 1.276

4.  Prevalence of thrombotic risk factors in Chinese Budd-Chiari syndrome patients: results of a prospective validation study.

Authors:  Xingshun Qi; Feifei Wu; Daiming Fan; Guohong Han
Journal:  Eur J Gastroenterol Hepatol       Date:  2014-05       Impact factor: 2.566

5.  Budd-Chiari syndrome: a prospective analysis of hepatic vein obstruction on ultrasonography, multidetector-row computed tomography and MR imaging.

Authors:  Sid Ahmed Faraoun; Mohamed El Amine Boudjella; Nabil Debzi; Nawel Afredj; Youcef Guerrache; Naima Benidir; Chafik Bouzid; Kamel Bentabak; Philippe Soyer; Salah Eddine Bendib
Journal:  Abdom Imaging       Date:  2015-08

6.  TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy.

Authors:  Antonia Perelló; Juan Carlos García-Pagán; Rosa Gilabert; Yanette Suárez; Eduardo Moitinho; Francisco Cervantes; Juan Carlos Reverter; Angels Escorsell; Jaume Bosch; Juan Rodés
Journal:  Hepatology       Date:  2002-01       Impact factor: 17.425

7.  Prevalence of JAK29V617F) mutation in intra-abdominal venous thrombosis.

Authors:  Amarapurkar Deepak; Sundeep Punamiya; Nikhil Patel; Sunil Parekh; Shilpa Mehta; Nirali Shah
Journal:  Trop Gastroenterol       Date:  2011 Oct-Dec

Review 8.  Hepatic outflow obstruction (Budd-Chiari syndrome). Experience with 177 patients and a review of the literature.

Authors:  J B Dilawari; P Bambery; Y Chawla; U Kaur; S R Bhusnurmath; H S Malhotra; G K Sood; S K Mitra; S K Khanna; B S Walia
Journal:  Medicine (Baltimore)       Date:  1994-01       Impact factor: 1.889

9.  The JAK2(V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis.

Authors:  C Goulding; B Uttenthal; L Foroni; V Duke; A Traore; P Kottaridis; A V Hoffbrand; D Patch; C McNamara
Journal:  Int J Lab Hematol       Date:  2008-10       Impact factor: 2.877

10.  Etiology, management, and outcome of the Budd-Chiari syndrome.

Authors:  Sarwa Darwish Murad; Aurelie Plessier; Manuel Hernandez-Guerra; Federica Fabris; Chundamannil E Eapen; Matthias J Bahr; Jonel Trebicka; Isabelle Morard; Luc Lasser; Joerg Heller; Antoine Hadengue; Philippe Langlet; Helena Miranda; Massimo Primignani; Elwyn Elias; Frank W Leebeek; Frits R Rosendaal; Juan-Carlos Garcia-Pagan; Dominique C Valla; Harry L A Janssen
Journal:  Ann Intern Med       Date:  2009-08-04       Impact factor: 25.391

View more
  12 in total

Review 1.  Cardiovascular disease in patients with autoinflammatory syndromes.

Authors:  Rainer Hintenberger; Agnes Falkinger; Kathrin Danninger; Herwig Pieringer
Journal:  Rheumatol Int       Date:  2017-11-01       Impact factor: 2.631

Review 2.  Malignant Venous Obstruction: Superior Vena Cava Syndrome and Beyond.

Authors:  Tamir Friedman; Keith B Quencer; Sirish A Kishore; Ronald S Winokur; David C Madoff
Journal:  Semin Intervent Radiol       Date:  2017-12-14       Impact factor: 1.513

3.  Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL).

Authors:  Akash Shukla; Ananta Shreshtha; Amar Mukund; Chhagan Bihari; C E Eapen; Guohong Han; Hemant Deshmukh; Ian Homer Y Cua; Cosmas Rinaldi Adithya Lesmana; Mamun Al Meshtab; Masayoshi Kage; Roongruedee Chaiteeraki; Sombat Treeprasertsuk; Suprabhat Giri; Sundeep Punamiya; Valerie Paradis; Xingshun Qi; Yasuhiko Sugawara; Zaigham Abbas; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2021-07-08       Impact factor: 6.047

4.  Timing of Transjugular Intrahepatic Portosystemic Stent-shunt in Budd-Chiari Syndrome: A UK Hepatologist's Perspective.

Authors:  Faisal Khan; Homoyon Mehrzad; Dhiraj Tripathi
Journal:  J Transl Int Med       Date:  2018-10-09

5.  Outcomes of endovascular interventional therapy for primary Budd-Chiari syndrome caused by hepatic venous obstruction.

Authors:  De-Lei Cheng; Nan Zhu; Hao Xu; Cheng-Li Li; Wei-Fu Lv; Wei-Wei Fang; Chuan-Ting Li
Journal:  Exp Ther Med       Date:  2018-09-07       Impact factor: 2.447

6.  Trapped vessel of abdominal pain with hepatomegaly: A case report.

Authors:  Sirisha Grandhe; Joy A Lee; Ankur Chandra; Christopher Marsh; Catherine T Frenette
Journal:  World J Hepatol       Date:  2018-11-27

7.  Complementary Role of Intervention Radiology in Palliative Care in Oncology Setting.

Authors:  Ekta Dhamija; Ashwin Deshmukh; Pankaj Meena; Mukesh Kumar; Sushma Bhatnagar; Sanjay Thulkar
Journal:  Indian J Palliat Care       Date:  2019 Jul-Sep

8.  A case report of membranous occlusion of the subclavian vein: a rare cause of McCleery syndrome.

Authors:  Jingjing Yin; Zhenhong Qi; Yu Chen; Yuexin Chen
Journal:  Ann Transl Med       Date:  2021-01

Review 9.  An Update on the Management of Budd-Chiari Syndrome.

Authors:  A Sharma; S N Keshava; A Eapen; E Elias; C E Eapen
Journal:  Dig Dis Sci       Date:  2020-07-20       Impact factor: 3.199

Review 10.  Transjugular intrahepatic portosystemic shunt for Budd-Chiari syndrome: A comprehensive review.

Authors:  Riccardo Inchingolo; Alessandro Posa; Martin Mariappan; Tiago Kojun Tibana; Thiago Franchi Nunes; Stavros Spiliopoulos; Elias Brountzos
Journal:  World J Gastroenterol       Date:  2020-09-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.